Cover Image
市場調查報告書

過敏免疫療法的全球市場:2016∼2020年

Global Allergy Immunotherapies Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 362098
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
過敏免疫療法的全球市場:2016∼2020年 Global Allergy Immunotherapies Market 2016-2020
出版日期: 2016年07月01日 內容資訊: 英文 87 Pages
簡介

過敏有各種種類,重度的過敏也可能致死。過敏反應的重病度與組織的恰當功能有關聯。全球過敏免疫療法市場,預計2016∼2020年,以年複合成長率7.3%擴大。

本報告提供全球過敏免疫療法市場現狀與到2020年的預測,市場規模與銷售趨勢,彙整主要供應商的競爭環境與簡介。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 過敏:概要

  • 過敏疾病的罹患率

第6章 開發平台分析

第7章 市場情況

  • 市場概要
  • 市場規模與預測

第8章 過敏免疫療法的各產品市場區隔

  • SCIT
  • SLITD
  • SLITT

第9章 過敏免疫療法的各地區市場區隔

  • 歐洲
  • 德國
  • 法國
  • 北美
  • 美國
  • 其他地區

第10章 過敏免疫療法的推動市場的要素

  • 未滿足需求高
  • 開發平台的新分子的存在
  • 與香煙消費量高有關聯的過敏性鼻炎和氣喘的增加
  • 環境污染的擴大造成過敏的增加

第11章 促進要素的影響

第12章 過敏免疫療法市場課題

第13章 促進要素與課題的影響

第14章 過敏免疫療法的市場趨勢

第15章 供應商環境

  • 競爭模式
  • ALK-Abello
  • Stallergenes
  • Merck Group
  • Allergy Therapeutics
  • 其他值得注意的供應商

第16章 附錄

第17章 關於Technavio

目錄
Product Code: IRTNTR9822

About the Allergy Immunotherapies Market

Immunotherapy, often referred to as desensitization, is the closest thing to a cure for allergic diseases and is an established treatment for severe allergies such as allergic rhinitis and allergic asthma. Its administration includes increasing the doses of allergen extracts over a span of time either through injections or sublingual tablets and drops.

Allergies occur when a foreign substance, which is mostly harmless, reacts with the immune system. These foreign substances are called allergens. Some allergens that affect the immune system are animal dander, dust mite, pollens, cockroach, and mold. Animal dander, dust mite, and mold cause indoor allergies.

There are various types of allergies, including rhinitis, asthma, eye allergy, and skin allergy. Sometimes, severe allergies can lead to death, as the severity of these allergic reactions interfere with the proper function of organs. For instance, allergic rhinitis and asthma cause the lungs to function poorly.

Technavio's analysts forecast the global allergy immunotherapies market to grow at a CAGR of 7.3% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global allergy immunotherapies market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat allergic diseases such as allergic rhinitis and allergic asthma. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Europe
  • North America
  • ROW

Technavio's report, Global Allergy Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ALK-Abello
  • Stallergenes
  • Merck Group
  • Allergy Therapeutics

Other Prominent Vendors

  • Adamis Pharmaceuticals
  • Aimmune Therapeutics
  • Anergis
  • ASIT biotech
  • Biomay
  • Circassia
  • DBV Technologies
  • Genentech
  • HAL Allergy
  • Laboratorios LETI
  • Mitsubishi Tanabe Pharma
  • Nycomed
  • Sementis
  • Shionogi
  • Torii
  • Tunitas Therapeutics
  • VentiRx Pharmaceuticals
  • Verona Pharma

Market driver

  • Presence of high unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Poor patient adherence and high dropout rates
  • For a full, detailed list, view our report

Market trend

  • Advent of SPIRE
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market Overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Allergies: Overview

  • Prevalence of allergic diseases

PART 06: Pipeline analysis

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by product type

  • Global SCIT market
  • Global SLITD market
  • Global SLITT market

PART 09: Geographical segmentation

  • Allergy immunotherapies market in Europe
  • Allergy immunotherapies market in Germany
  • Allergy immunotherapies market in France
  • Allergy immunotherapies market in North America
  • Allergy immunotherapies market in US
  • Allergy immunotherapies market in ROW

PART 10: Market drivers

  • Presence of high unmet medical needs
  • Existence of novel molecules in pipeline
  • Increasing prevalence of allergic rhinitis and asthma coupled with high consumption of tobacco
  • Upsurge of allergies due to increase in environmental pollution

PART 11: Impact of drivers

PART 12: Market challenges

  • Increased preference for CAM
  • Poor patient adherence and high dropout rates
  • High cost of allergic immunotherapy

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of SLITT
  • Advent of SPIRE
  • Strategic alliances for novel drug developments
  • Identification of new allergen targets

PART 15: Vendor landscape

  • Competitive scenario
  • ALK-Abello
  • Stallergenes
  • Merck Group
  • Allergy Therapeutics
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Impact of key customer segments 2015
  • Exhibit 03: Prevalence of HDM allergies in major countries 2015
  • Exhibit 04: Incidence of allergies 1920-2020 (% of population)
  • Exhibit 05: Prevalence of allergies in US 2015
  • Exhibit 06: Prevalence of allergies in Europe 2015
  • Exhibit 07: Global allergy immunotherapies market: Pipeline portfolio
  • Exhibit 08: Global allergy immunotherapies market according to drug phase 2015
  • Exhibit 09: Major pipeline events for allergy immunotherapies 2016-2017
  • Exhibit 10: Global allergy immunotherapies market snapshot: Developed and emerging markets 2015
  • Exhibit 11: Growth opportunities for global allergy immunotherapies market
  • Exhibit 12: Global allergy immunotherapies market 2015-2020 ($ billions)
  • Exhibit 13: Comparison of active ingredients used in allergy immunotherapy
  • Exhibit 14: Major healthcare reforms in global allergy immunotherapies market
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Global allergy immunotherapy market segmentation by product type 2015
  • Exhibit 17: Advantages of short-course SCITs
  • Exhibit 18: Opportunity analysis of global SCIT market
  • Exhibit 19: Global SCIT market 2015-2020 ($ millions)
  • Exhibit 20: Opportunity analysis of global SLITD market
  • Exhibit 21: Global SLITD market 2015-2020 ($ millions)
  • Exhibit 22: Opportunity analysis of global SLITT market
  • Exhibit 23: Global SLITT market 2015-2020 ($ millions)
  • Exhibit 24: Comparison between whole allergen immunotherapies, SCIT, and SLIT
  • Exhibit 25: Global allergy immunotherapies market segmentation by product type 2015-2020 ($ millions)
  • Exhibit 26: Global allergy immunotherapies market segmentation by product type 2015-2020
  • Exhibit 27: Global allergy immunotherapies market: YoY revenue and growth based on product type 2015-2020 ($ millions)
  • Exhibit 28: Global allergy immunotherapies market: Geography outlook (2015-2020)
  • Exhibit 29: Revenue and growth outlook in different countries 2015
  • Exhibit 30: Global allergy immunotherapies market by geographical segmentation 2015
  • Exhibit 31: Allergy immunotherapies market in Europe 2015-2020 ($ millions)
  • Exhibit 32: Market share of SLITT and SCIT/SLITD in Europe 2015
  • Exhibit 33: Market share of allergy immunotherapies in Europe
  • Exhibit 34: Allergy immunotherapies market in Germany 2015-2020 ($ millions)
  • Exhibit 35: Allergy immunotherapies market in France 2015-2020 ($ millions)
  • Exhibit 36: Allergy immunotherapies market in North America 2015-2020 ($ millions)
  • Exhibit 37: Market share of SLITT and SCIT/SLITD in North America 2015
  • Exhibit 38: Allery immunotherapies market in North America
  • Exhibit 39: Market share of allergy immunotherapies in North Americas
  • Exhibit 40: Allergy immunotherapies market in US 2015-2020 ($ millions)
  • Exhibit 41: Allergy immunotherapies market in ROW 2015-2020 ($ millions)
  • Exhibit 42: Global allergy immunotherapies market revenue by geography 2015-2020 ($ millions)
  • Exhibit 43: Global allergy immunotherapies market revenue by geography 2015-2020
  • Exhibit 44: Global allergy immunotherapies market: YoY revenue and growth based on geography 2015-2020 ($ millions)
  • Exhibit 45: Unmet medical needs for severely affected individuals: Key allergens and severe allergic cases
  • Exhibit 46: Impact of drivers
  • Exhibit 47: Use of CAM therapies among individuals in US
  • Exhibit 48: Comparison of different cost components of allergy immunotherapy ($) 2014
  • Exhibit 49: Impact of drivers and challenges
  • Exhibit 50: Advantages of SPIRE allergy therapies
  • Exhibit 51: Market share analysis
  • Exhibit 52: Market position of top vendors 2015
  • Exhibit 53: Competitive position of vendors
  • Exhibit 54: Key vendors: Geographical presence 2015
  • Exhibit 55: Market share analysis in US
  • Exhibit 56: Market share analysis in Europe
  • Exhibit 57: Business segmentation by revenue 2015
  • Exhibit 58: ALK-Abello: YoY revenue and growth rate of SCIT/SLIT drops 2013-2015 ($ millions)
  • Exhibit 59: Geographic segmentation of SCIT/SLIT drops 2015
  • Exhibit 60: ALK-Abello: YoY revenue and growth rate of SLIT tablets 2013-2015 ($ millions)
  • Exhibit 61: ALK-Abello: Geographic segmentation of SLIT tablets 2015
  • Exhibit 62: ALK-Abello: Metrics analysis
  • Exhibit 63: Product categories by revenue
  • Exhibit 64: Stallergenes: Geographical segmentation by revenue 2015
  • Exhibit 65: Stallergenes: Metrics analysis
  • Exhibit 66: Allergopharma: YoY revenue and growth rate of allergy immunotherapy products 2013-2015 ($ millions)
  • Exhibit 67: Merck Group: Metrics analysis
  • Exhibit 68: Allergy Therapeutics: YoY revenue and growth rate of key allergy immunotherapies 2013-2015 ($ millions)
  • Exhibit 69: Allergy Therapeutics: Products by revenue 2015
  • Exhibit 70: Allergy Therapeutics: Geographical segmentation by revenue 2015
  • Exhibit 71: Allergy Therapeutics: Metrics analysis
Back to Top